Minor Cannabinoids
A group of federal health agencies has indicated in a government publication that they’d like to study various “minor cannabinoids” from marijuana and cannabis terpenes to determine how they could best be used to treat a handful of medical ailments.
According to a notice published by the National Institutes of Health, eight of the agency’s affiliates hope to fund studies into medical marijuana.
The studies will specialize in cannabinoids such as CBD, CBN, CBG, and delta-8 THC, rather than the commonly known delta-9 THC, the first cannabinoid in marijuana that gives consumers a high.
Agencies Promoting Research
The National Center for Complementary and Integrative Health wants to review “minor cannabinoids and terpenes in the cannabis plant as it relates to pain.”
The National Cancer Institute wants to review “the mechanisms by which minor cannabinoids and terpenes in the cannabis plant may affect cancer interception, cancer treatment and resistance, and management of cancer symptoms.”
Also read – UK Parliamentary Group’s Curious Fantasy: 220,000 Hectares Of Hemp By 2027
The National Eye Institute wants to review the “therapeutic benefits of terpenes and minor cannabinoids in the treatment of glaucoma, retinal degenerations, and uveitis.”
The National Institute on Aging wants to review cannabinoid and terpene impacts on “age-related cognitive decline/impairment, Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD), weight loss/cachexia, sleep, or conditions in palliative care settings.”
The National Institute on alcohol abuse and Alcoholism wants to review “the role of endocannabinoid systems in alcohol misuse and alcohol use disorder.”
Also read – Five Pet CBD Companies with Innovative Products.
The National Institute on substance abuse wants to review “minor cannabinoids in the context of substance use and substance use disorder (SUD), and comorbidity of SUD and HIV infection.”
The National Institute of Dental and Craniofacial Research wants to review the “therapeutic properties of minor cannabinoids and terpenes for dental, oral or craniofacial diseases or conditions.”
The National Institute of Neurological Disorders and Stroke wants to review minor cannabinoids and terpenes’ effects on “pain, migraine, headache, epilepsy, movement disorders, neurodegenerative disorders, and stroke.”
